Compare Crispr Therapeutics AG (CRSP) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Skyworks Solutions Inc — how do they compare? Crispr Therapeutics AG trades at $50.67 (market cap $4.97B), while Skyworks Solutions Inc trades at $56.91 (market cap $8.51B). The key difference: Skyworks Solutions Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 5.02% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SWKS | |
|---|---|---|
Market Cap | $4.97B | $8.51B |
Sector | Health | Technology |
52-Week High | $76.78 | $83.40 |
52-Week Low | $44.34 | $52.50 |
Enterprise Value | $3.32B | $8.28B |
Dividend Yield | — | 5.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Skyworks Solutions (SWKS) trades at $58.24, down 3.51% amid bearish technical signals, though recent earnings beats and a 60% analyst buy rating suggest underlying strength. The company maintains solid fundamentals with $4.09B revenue and 8.93% net margin, while expanding into AI and EV markets through recent product launches. Cash flow trends show variability, with 2025 net cash flow negative at -$207M after positive flows in prior years.
The stock presents a value opportunity with consensus price target of $72.56 offering 25% upside, supported by dividend yield above 4% and strategic positioning in growing semiconductor segments. Key risks include ongoing legal investigations and customer concentration, but strong analyst support and technical oversold conditions near support at $55 indicate potential for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
